Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
Susan Bal(University of Alabama at Birmingham Hospital), Myo Htut(City of Hope), Allison Kaeding(Bristol-Myers Squibb (United States)), Daniel Egan, Larry D. Anderson(Dana-Farber Cancer Institute), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Jesús G. Berdeja(Tennessee Oncology), Omar Nadeem(Harvard University), Mehmet H. Kocoglu(University of Maryland, Baltimore), Thomas G. Martin(University of California San Francisco Medical Center), Naomey Sarkis(Bristol-Myers Squibb (United States)), Michael R. Burgess(Bristol-Myers Squibb (United States)), Wei-Ming Kao(Bristol-Myers Squibb (United States)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Alok Shrestha(Bristol-Myers Squibb (United States)), Jinjie Chen(Bristol-Myers Squibb (United States)), Luciano J. Costa(University of Alabama at Birmingham), Chaoqun Mei(Bristol-Myers Squibb (United States)), Tara B. Gregory(Sarah Cannon)
Cited by 23
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505